Marta Aymerich
- Genetics top 2%
- Chronic Lymphocytic Leukemia Research 14
- Hematology top 2%
- Multiple Myeloma Research and Treatments 5
- Hematopoietic Stem Cell Transplantation 2
-
- Lymphoma Diagnosis and Treatment 8
- Immunology top 10%
- Immunodeficiency and Autoimmune Disorders 5
-
- Glycosylation and Glycoproteins Research 2
- Protein Degradation and Inhibitors 2
-
- Neonatal Health and Biochemistry 2
In The Last Decade
Marta Aymerich
25 papers receiving 1.0k citations
Hit Papers
Peers
Comparison fields: 5 of 64
- Genetics 397
- Hematology 365
- Pathology and Forensic Medicine 343
- Immunology 224
- Cancer Research 129
Countries citing papers authored by Marta Aymerich
This map shows the geographic impact of Marta Aymerich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marta Aymerich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marta Aymerich more than expected).
Fields of papers citing papers by Marta Aymerich
This network shows the impact of papers produced by Marta Aymerich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marta Aymerich. The network helps show where Marta Aymerich may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Marta Aymerich, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 8 | |
| 2 | 2021 | 1 | |
| 3 | 2020 | 42 | |
| 4 | 2020 | 3 | |
| 5 | 2018 | 5 | |
| 6 | Non-coding recurrent mutations in chronic lymphocytic leukaemiabreakdown → | 2016 | 377 |
| 7 | 2015 | 18 | |
| 8 | 2015 | 58 | |
| 9 | 2013 | 3 | |
| 10 | 2012 | 44 | |
| 11 | 2012 | 20 | |
| 12 | 2008 | 1 | |
| 13 | 2006 | 23 | |
| 14 | 2005 | 28 | |
| 15 | 2004 | 59 | |
| 16 | 2003 | 25 | |
| 17 | 2003 | 95 | |
| 18 | 2003 | 10 | |
| 19 | CD34+ selected autologous peripheral blood stem cell transplantation for multiple sclerosis: report of toxicity and treatment results at one year of follow-up in 15 patients. | 2003 | 93 |
| 20 | 2002 | 8 |
About Marta Aymerich
Marta Aymerich is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine, having authored 25 papers that have together received 1.0k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (14 papers), Lymphoma Diagnosis and Treatment (8 papers), Immunodeficiency and Autoimmune Disorders (5 papers), Multiple Myeloma Research and Treatments (5 papers), Glycosylation and Glycoproteins Research (2 papers), Neonatal Health and Biochemistry (2 papers), Protein Degradation and Inhibitors (2 papers) and Hematopoietic Stem Cell Transplantation (2 papers). The work is most often cited by research in Genetics (397 citations), Hematology (365 citations) and Pathology and Forensic Medicine (343 citations). Marta Aymerich has collaborated with scholars based in Spain, France and Andorra. Frequent co-authors include Neus Villamor, Elı́as Campo, Carlos López-Otı́n, Tycho Baumann, José I. Martı́n-Subero, Emili Montserrat, Marı́a Rozman, Renée Beekman, Rafael Valdés‐Mas and Carlota Rubio-Pérez. Their work appears in journals such as Nature, Blood and The Journal of Infectious Diseases.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.